MicroSigX's M3CRC Revolutionizes Colorectal Cancer Screening with Proven Success and Growing Recognition
We are thrilled to announce that our M3 bacterial gene-marker test has been recognized in the 2023 Joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines for diagnosing colorectal neoplasia, published in the British Medical Journal – Gut. This endorsement highlights M3CRC's exceptional sensitivity and reliability.
"Our microbial-based, non-invasive test offers superior sensitivity in detecting colorectal cancer (CRC) and advanced adenomas compared to other non-invasive methods like FIT and mt-sDNA. Being recognized by APAGE and APSDE guidelines validates our technology's effectiveness and reliability in clinical practice," said Rachel Fan, CEO of MicroSigX.
The latest Multi-Center Clinical Study of M3CRC, involving nine centers in the Asia-Pacific region, is crucial for further validating these findings across diverse populations. Initial results, to be announced in May 2025, aim to prove the test's adaptability and effectiveness on a wider scale, paving the way for widespread implementation. Initial results from Hong Kong, Japan, and Singapore cohorts mark an important milestone in our mission to revolutionize CRC screening.
CUHK research investigator Dr. Louis Ho Shing Lau will present the initial results at Digestive Disease Week (DDW) 2025, a prestigious conference in gastroenterology. DDW attracts top researchers and clinicians from around the world, offering unparalleled visibility and recognition for innovative research.
Stay tuned for more updates!
#DDW2025
#MicroSigX
#M3CRC
#ColorectalCancer
#CancerScreening
#Innovation
GenieBiome Limited 精進微生物科技有限公司
Microbiota I-Center (MagIC) (香港微生物菌群創新中心)
CUHK Medicine
